设为首页收藏本站
开启辅助访问
切换到窄版

 找回密码
 注册

QQ登录

只需一步,快速开始

搜索
查看: 289|回复: 0

靶向ErbB的CAR-T细胞免疫治疗癌症

[复制链接]
发表于 2016-1-26 11:05:52 | 显示全部楼层 |阅读模式
ErbB-targeted CAR T-cell immunotherapy of cancer.
Chimeric antigen receptor (CAR) based immunotherapy has been under development for the last 25 years and is now a promising new treatment modality in the field of cancer immunotherapy. The approach involves genetically engineering T cells to target malignant cells through expression of a bespoke fusion receptor that couples an HLA-independent antigen recognition domain to one or more intracellular T-cell activating modules. Multiple clinical trials are now underway in several centers to investigate CAR T-cell immunotherapy of diverse hematologic and solid tumor types. The most successful results have been achieved in the treatment of patients with B-cell malignancies, in whom several complete and durable responses have been achieved. This review focuses on the preclinical and clinical development of CAR T-cell immunotherapy of solid cancers, targeted against members of the ErbB family.
KEYWORDS:
ErbB receptors; HER2; T cells; cancer; chimeric antigen receptor; immunotherapy

靶向ErbB的CAR-T细胞免疫治疗癌症
嵌合抗原受体(CAR)为基础的免疫治疗已经发展了将近25年了,并且现在在癌症免疫治疗领域,已经成为一种很有前途的新的治疗方式。这种方法涉及了一个靶向肿瘤细胞的修饰过的T细胞,通过T细胞表面表达一种定制的融合受体,受体包含了一个HLA独立抗原识别领域,能够引起一个或多个细胞内的T细胞激活模块。在几个中心的多中心临床试验正在进行中,以探讨CAR-T技术对不同的血液和实体肿瘤的免疫治疗作用。在治疗B细胞恶性肿瘤的患者中已经取得了最成功的结果,已经出现不少完整和持久的反应。本文综述了对抗实体癌症,针对ErbB家族成员CAR-T细胞免疫疗法的临床前和临床开发。
关键词:
ErbB受体;HER2T细胞;癌;嵌合抗原受体;免疫治疗
出自爱康得生物技术

您需要登录后才可以回帖 登录 | 注册

本版积分规则

QQ|申请友链|小黑屋|手机版|Archiver|生物信息学论坛 ( 蜀ICP备09031721号  

GMT+8, 2017-1-17 10:53 , Processed in 0.190643 second(s), 20 queries .

Powered by Discuz! X3

© 2001-2013 Comsenz Inc.

快速回复 返回顶部 返回列表